Darling Ingredients Inc. (DAR): A Bull Case Theory 

We came across a bullish thesis on Darling Ingredients Inc. on Valueinvestorsclub.com by TallGuy. In this article, we will summarize the bulls’ thesis on DAR. Darling Ingredients Inc.’s share was trading at $37.01 as of December 2nd. DAR’s trailing and forward P/E were 54.88 and 11.07  respectively according to Yahoo Finance. Copyright: mikkolem / 123RF Stock Photo Darling […]

Weight loss drugs fill a gap for women with hormonal disorder PCOS | REUTERS

Many women with PCOS say they struggled for years to get a diagnosis and effective treatment. Now, more are finding relief as GLP-1 prescriptions for PCOS rose over sevenfold in the US since 2021. #pcos #glp1 #novonordisk #elililly #hormonaldisorder #News #Reuters #Newsfeed Read the story here: https://reut.rs/4rGTKhD 👉 Subscribe: http://smarturl.it/reuterssubscribe Keep up with the latest […]

GLP-1s may not affect obesity-related cancer risk: Study 

A new study from researchers at Cambridge, Mass.-based Harvard University found that blockbuster GLP-1 drugs such as Ozempic and Zepbound may have a minimal effect on an individual’s risk of developing obesity-related cancers.  The study, published Dec. 9 in Annals of Internal Medicine, is based on a review of 48 randomized controlled trials involving 94,245 […]

Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes

Diabetology, Vol. 6, Pages 161: Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes Diabetology doi: 10.3390/diabetology6120161 Authors: Scott Reule Sean Pickthorn Stefanie Worwa Areef Ishani Robert Foley Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists […]

1 Major Factor Behind the Healthcare Sector’s Recent Surge

Key Points Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other companies are soaring on new drugs or the growth of existing ones. 10 stocks we like better than Eli Lilly › The healthcare sector has vastly outperformed the broader market in recent weeks. The S&P […]